EHA 2024: Updates in the Treatment of CLL    - Episode 17

EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

, , , ,

The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.

EP. 1: Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024
EP. 2: Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL
EP. 3: Frontline BTKi Selection
EP. 4: Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib
EP. 5: Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy
EP. 6: Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL
EP. 7: EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches
EP. 8: Navigating Treatment Approaches for R/R CLL
EP. 9: How Experts View MAIC Data That was Presented at EHA 2024
EP. 10: BTKi Intolerance in Real-world Practice & Management Strategy
EP. 11: Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities
EP. 12: Approach to Hypertension Management With BTKi Treatment
EP. 13: Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib
EP. 14: Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing
EP. 15: Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice
EP. 16: TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices
Now Viewing
EP. 17: EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL
EP. 18: Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673
EP. 19: Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL
EP. 20: Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies
EP. 21: Clinical Pearls and Impacts to Practice from EHA 2024

Video content above is prompted by the following:

  • Briefly share perspective/insights on emerging novel agents in R/R CLL: BTKi degraders

Related Content:

EHA 2024: Updates in the Treatment of CLL   UCI Health Chao Family Comprehensive Cancer CenterDana-Farber Cancer InstituteMayo ClinicColumbia University Herbert Irving Comprehensive Cancer CenterCity of HopeChronic Lymphocytic LeukemiaOncLive Peer Exchange®
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers for 2024
EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL
Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL